Daiichi Sankyo (Germany)

Recent papers from Daiichi Sankyo (Germany)

1. Renal Function and 4‐Year Outcomes in Edoxaban‐Treated Patients: A Sub‐Analysis From the ETNA ‐ AF Europe StudyEuropean Journal of Clinical Investigation · 2026
2. Predicted change in 10-year cardiovascular risk one year after initiation of bempedoic acid-based therapy in the MILOS studyEuropean Heart Journal · 2026
3. Real-world use of bempedoic acid in women and men: pooled 1-year follow-up data from the observational, prospective, real-world MILOS study in Austria, Belgium, Germany, Italy, and the United KingdomEuropean Heart Journal · 2026
4. Bempedoic acid for LDL-cholesterol management in patients with and without diabetes: insights from the MILOS studyEuropean Heart Journal · 2026
5. Risk stratification and long-term outcomes in patients with chest pain and cardiac troponin flat curveEuropean Heart Journal · 2026
6. Feasibility Assessment of a Single‐pH Connected Polishing Train for Monoclonal Antibody Purification Using Mildly Acidic Protein A Elution and an Acidic‐Window Anion Exchange MembraneBiotechnology and Bioengineering · 2026
7. Investigation of the mechanisms and modulation of irinotecan‐induced emesis in Suncus murinusBritish Journal of Pharmacology · 2026
8. Effectiveness and Safety of Bempedoic Acid in Routine Clinical Practice: 1-Year Follow-Up Data From Milos Belgian CohortAtherosclerosis · 2026
9. Comparable LDL-C Reductions With Bempedoic Acid Used Alone or With Background Statin and/or Ezetimibe Therapy: Real World Evidence From the Milos StudyAtherosclerosis · 2026
10. Real-World Use of Bempedoic Acid in Spain: 8-Week Results From the Milos StudyAtherosclerosis · 2026
11. Real-World Effectiveness and Safety of Bempedoic Acid: Insights From the 1-Year Follow-Up Italian Cohort Data of the Milos StudyAtherosclerosis · 2026
12. Real-World One-Year Data on the Use of Bempedoic Acid in Patients With Dyslipidemia: Insights From the Milos Austria StudyAtherosclerosis · 2026
13. Swiss Real-World Experience With Bempedoic Acid in Dyslipidaemia: 8-Week Results From the Observational, Prospective Milos StudyAtherosclerosis · 2026
14. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver DiseaseJournal of the American College of Cardiology · 2019
15. Early Direct Oral Anticoagulant Initiation After Intracranial Hemorrhage Among Japanese Patients With Nonvalvular Atrial Fibrillation ― SAFE-ICH Registry 12-Month Outcomes ―Circulation Reports · 2026
16. MuSK agonistic antibody has therapeutic potential for MuSK antibody-positive myasthenia gravisNeurotherapeutics · 2026
17. The strength of a gene’s first 5’ splice site is a key determinant of its expression2026
18. Development of Potent and Orally Bioavailable MALT1 Inhibitors for Sjogren’s Syndrome: Efficacy and Safety AssessmentACS Medicinal Chemistry Letters · 2026
19. Optical Attenuation Analysis of Biofilm Formation on Dental Prostheses Using Time-Domain Optical Coherence Tomography and Atomic Force MicroscopyDentistry Journal · 2026
20. Single-molecule insights into SAM-I riboswitch ligand binding using scaled magnetic force spectroscopy with comparison to conventional biophysical methodsRNA Biology · 2026